326 related articles for article (PubMed ID: 36707911)
21. m
Wang L; Hu X; Liu X; Feng Y; Zhang Y; Han J; Liu X; Meng F
Front Immunol; 2022; 13():1022720. PubMed ID: 36389726
[TBL] [Abstract][Full Text] [Related]
22. m
Wu Y; Li L; Wang L; Zhang S; Zeng Z; Lu J; Wang Z; Zhang Y; Zhang S; Li H; Chen T
BMC Cancer; 2024 Apr; 24(1):506. PubMed ID: 38649860
[TBL] [Abstract][Full Text] [Related]
23. Molecular phenotypic linkage between N
Zhang F; Bi J; Liao J; Zhong W; Yu M; Lu X; Che J; Chen Z; Xu H; Hu S; Liu Y; Guo S
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6901-6916. PubMed ID: 36826593
[TBL] [Abstract][Full Text] [Related]
24. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
25. Genome-Wide Analysis of Prognostic lncRNAs, miRNAs, and mRNAs Forming a Competing Endogenous RNA Network in Hepatocellular Carcinoma.
Lin P; Wen DY; Li Q; He Y; Yang H; Chen G
Cell Physiol Biochem; 2018; 48(5):1953-1967. PubMed ID: 30092571
[TBL] [Abstract][Full Text] [Related]
26. Crosstalk of RNA methylation writers defines tumor microenvironment and alisertib resistance in breast cancer.
Zhang X; Shen L; Zhu Y; Zhai C; Zeng H; Liu X; Tao J
Front Endocrinol (Lausanne); 2023; 14():1166939. PubMed ID: 37818090
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Analysis of N6-Methyladenosine (m
Liu D; Yuan M; Wang Z; Sun L; Fang Y; Ma X; Zhang L; Xing Y; Zhu J; Liu Y; Zhu W; Bao S; Jia Y; Wang Y
Can J Gastroenterol Hepatol; 2022; 2022():3506518. PubMed ID: 36452120
[TBL] [Abstract][Full Text] [Related]
28. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.
Deng M; Fang L; Li SH; Zhao RC; Mei J; Zou JW; Wei W; Guo RP
Mutagenesis; 2021 Oct; 36(5):369-379. PubMed ID: 34467992
[TBL] [Abstract][Full Text] [Related]
29. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
30. RNA modification "writer"-mediated RNA modification patterns and tumor microenvironment characteristics of cervical cancer.
Qu Y; Zhu H; Kong C; Zheng X; Wang D; Chen X; Yuan D
Clin Transl Oncol; 2022 Jul; 24(7):1413-1424. PubMed ID: 35220552
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
[TBL] [Abstract][Full Text] [Related]
32. Bioinformatics analysis of the interactions among lncRNA, miRNA and mRNA expression, genetic mutations and epigenetic modifications in hepatocellular carcinoma.
Lin C; Yuan G; Hu Z; Zeng Y; Qiu X; Yu H; He S
Mol Med Rep; 2019 Feb; 19(2):1356-1364. PubMed ID: 30535497
[TBL] [Abstract][Full Text] [Related]
33. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
[TBL] [Abstract][Full Text] [Related]
34. RNA modification writers influence tumor microenvironment in gastric cancer and prospects of targeted drug therapy.
Song P; Zhou S; Qi X; Jiao Y; Gong Y; Zhao J; Yang H; Qian Z; Qian J; Tang L
J Bioinform Comput Biol; 2022 Apr; 20(2):2250004. PubMed ID: 35287562
[No Abstract] [Full Text] [Related]
35. Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma.
Wu ZH; Yang DL; Wang L; Liu J
Front Immunol; 2021; 12():793343. PubMed ID: 34925377
[TBL] [Abstract][Full Text] [Related]
36. Multi-omics analysis and validation of the tumor microenvironment of hepatocellular carcinoma under RNA modification patterns.
Yao Y; Lv J; Wang G; Hong X
Math Biosci Eng; 2023 Sep; 20(10):18318-18344. PubMed ID: 38052560
[TBL] [Abstract][Full Text] [Related]
37. PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma.
Song F; Wang CG; Mao JZ; Wang TL; Liang XL; Hu CW; Zhang Y; Han L; Chen Z
Front Immunol; 2023; 14():1197152. PubMed ID: 37398672
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive analysis of N
Zhu HX; Lu WJ; Zhu WP; Yu S
J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
[TBL] [Abstract][Full Text] [Related]
39. RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer.
Zhou B; Bie F; Zang R; Zhang M; Song P; Liu L; Peng Y; Bai G; Zhao J; Gao S
EBioMedicine; 2022 Oct; 84():104268. PubMed ID: 36116215
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer.
Zhang Z; Chen P; Yun J
Front Genet; 2023; 14():1156095. PubMed ID: 37124622
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
